Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
ESMO 2024 – Torl challenges BioNTech in Claudin6
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
